

Datasheet for ABIN5207469

## Human **MAGEC1** CRISPR gRNA + Cas9 in Lenti Particles

### Overview

|              |  |
|--------------|--|
| Quantity:    | 3 x 300 µL   |
| Gene:        | MAGEC1   |
| Species:     | Human  |
| Insert:      | gRNA + Cas9  |
| Vector:      | Lentiviral Vector  |
| Application: | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN) |

### Product Details

|                       |  |
|-----------------------|--|
| Purpose:              | Set of 3 gRNA against MAGEC1 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (sgRNA and Cas9 in a single vector)  |
| Vector Backbone:      | pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro  |
| Promoter:             | U6 Promoter, SFFV Promoter   |
| Selectable Marker:    | Puromycin  |
| Bacterial Resistance: | Ampicillin   |
| Expression Type:      | Stable, Transient  |
| Sequence:             | Sequence available upon placing order  |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.<br>Cas9 Nuclease is under the control of the SFFV promoter which should work for a vast majority of cells, except ES cells or iPS cells. |
| Sequencing Primer:    | U6 Forward Primer: 5'--TACGTCCAAGGTCGGGCAGGAAGA--3'  |
| Components:           | Lentiviral particles with a set of 3 gRNAs (3 x 300 µL) covering different sequences of MAGEC1   |

Order at [www.genomics-online.com](http://www.genomics-online.com)

USA & Canada: +1 877 302 8632 | [support@antibodies-online.com](mailto:support@antibodies-online.com)

## Target Details

---

Gene: MAGEC1

Alternative Name: MAGEC1 ([MAGEC1 Products](#))

NCBI Accession: [NM\\_005462](#)

## Application Details

---

Application Notes: Recommended for quality control: Restriction Enzyme Digest and Sequencing

Restrictions: For Research Use only

## Handling

---

Format: Viral Particles

Storage: -80 °C

Expiry Date: 12 months

## Publications

---

Product cited in: Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, (1991)